Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated:  10/28/2015
Dominican and Watsonville Community Hospital
mi
from
Soquel, CA
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated: 10/28/2015
Dominican and Watsonville Community Hospital
mi
from
Soquel, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated:  10/28/2015
Los Robles Regional Medical Center
mi
from
Thousand Oaks, CA
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated: 10/28/2015
Los Robles Regional Medical Center
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated:  10/28/2015
Cancer Care Associates Medical Group
mi
from
Torrance, CA
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated: 10/28/2015
Cancer Care Associates Medical Group
mi
from
Torrance, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated:  10/28/2015
UCLA Cancer Center - Santa Clarita
mi
from
Valencia, CA
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated: 10/28/2015
UCLA Cancer Center - Santa Clarita
mi
from
Valencia, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated:  10/28/2015
Oncology Medical Center of North County
mi
from
Vista, CA
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated: 10/28/2015
Oncology Medical Center of North County
mi
from
Vista, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated:  10/28/2015
Valley Hematology and Oncology
mi
from
West Hills, CA
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated: 10/28/2015
Valley Hematology and Oncology
mi
from
West Hills, CA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated:  10/28/2015
Cancer Care Consultants
mi
from
Las Vegas, NV
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Phase II Study of Irinotecan (CPT-11) in Adenocarcinoma of the Esophagus and Gastric Cardia
Status: Enrolling
Updated: 10/28/2015
Cancer Care Consultants
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
Temozolomide For Patients With Cerebral Metastases Who Have Failed Radiation Therapy
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
Temozolomide For Patients With Cerebral Metastases Who Have Failed Radiation Therapy
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated:  10/28/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated: 10/28/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated:  10/28/2015
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated: 10/28/2015
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated:  10/28/2015
OHSU Cancer Institute
mi
from
Portland, OR
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract
Status: Enrolling
Updated: 10/28/2015
OHSU Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Liver Cancer
A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Liver Cancer
A Phase I/II Trial Testing Immunization With Dendritic Cells Pulsed With Four AFP Peptides in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Radiofrequency Ablation of Pulmonary Malignancy
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Radiofrequency Ablation of Pulmonary Malignancy
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CP-724,714 in Treating Patients With Metastatic Breast Cancer
A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
CP-724,714 in Treating Patients With Metastatic Breast Cancer
A Phase I Safety and Pharmacokinetic/Pharmacodynamic Study of CP-724, 714 In Patients With Metastatic HER2-Overexpressing Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated:  10/28/2015
Bladder Cancer Genitourinary Oncology, PC
mi
from
Phoenix, AZ
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated: 10/28/2015
Bladder Cancer Genitourinary Oncology, PC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated:  10/28/2015
Veterans Affairs Medical Center - West Los Angeles
mi
from
Los Angeles, CA
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated: 10/28/2015
Veterans Affairs Medical Center - West Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated:  10/28/2015
Santa Monica-UCLA Medical Center
mi
from
Santa Monica, CA
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated: 10/28/2015
Santa Monica-UCLA Medical Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated:  10/28/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
Parallel, Randomized, Double-Blind, Placebo Controlled Phase II Adjuvant Studies of Erlotinib and Polyphenon E to Prevent the Recurrence and Progression of Tobacco-Related, Superficial Bladder Cancer
Status: Enrolling
Updated: 10/28/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Bortezomib in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Bortezomib in Treating Patients With Metastatic Kidney Cancer
A Phase II Study of Bortezomib (Velcade ) Administered as a Single Agent in Metastatic Non-Clear Cell Renal Cell Carcinoma (RCC) Patients
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Status: Enrolling
Updated:  10/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation
Status: Enrolling
Updated: 10/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan-Kettering Cancer Center at Mercy
mi
from
Rockville Centre, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan-Kettering Cancer Center at Mercy
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Pilot Study of Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memoral Sloan Kettering Cancer Center@Phelps
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Expressive Writing and Adjustment to Metastatic Breast Cancer
Expressive Writing and Adjustment to Metastatic Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Expressive Writing and Adjustment to Metastatic Breast Cancer
Expressive Writing and Adjustment to Metastatic Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Phase II Trial of Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Phase II Trial of Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma
Status: Enrolling
Updated:  10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma
Status: Enrolling
Updated: 10/28/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/29/2015
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/29/2015
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/29/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Open-label, Phase 1 Trial to Evaluate the Safety and Pharmacokinetic Parameters of a 2-day Pulse of Intravenous (IV) AC480 (AC480IV) Administered as Monotherapy and in Combination With Docetaxel in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/29/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  10/29/2015
Montefiore Medical Center
mi
from
Bronx, NY
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 10/29/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated:  10/29/2015
Wilshire Oncology Medical Group, Incorporated - Pomona
mi
from
Pomona, CA
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer
Status: Enrolling
Updated: 10/29/2015
Wilshire Oncology Medical Group, Incorporated - Pomona
mi
from
Pomona, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Southern California Permanente Medical Group
mi
from
Downey, CA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Children's Hospital Central California
mi
from
Madera, CA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Connecticut Children's Medical Center
mi
from
Hartford, CT
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Childrens National Medical Center
mi
from
Washington,
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Miami Children's Hospital
mi
from
Miami, FL
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials